Cargando…

Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma

Precision medicine is modernizing strategies for clinical study design to help improve diagnoses guiding individualized treatment based on genetic or phenotypic characteristics that discriminate between patients with similar clinical presentations. Methodology to personalize treatment choices is bei...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nowakowski, Grzegorz S., Feldman, Tatyana, Rimsza, Lisa M., Westin, Jason R., Witzig, Thomas E., Zinzani, Pier Luigi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6522601/ https://www.ncbi.nlm.nih.gov/pubmed/31097684 http://dx.doi.org/10.1038/s41408-019-0208-6

Ejemplares similares

Whole-exome analysis reveals novel somatic genomic alterations associated with cell of origin in diffuse large B-cell lymphoma
por: Manso, B A, et al.
Publicado: (2017)

Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphoma
por: Desai, Sanjal H., et al.
Publicado: (2022)

Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma
por: Zinzani, Pier Luigi, et al.
Publicado: (2021)

The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma
por: Calabretta, Eleonora, et al.
Publicado: (2022)

Diffuse large B-cell lymphoma: new targets and novel therapies
por: Cheson, Bruce D., et al.
Publicado: (2021)

ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma
por: Nowakowski, Grzegorz S, et al.
Publicado: (2016)

Lymphoma immunotherapy
por: Zinzani, Pier Luigi
Publicado: (2018)

A Strategy for Full Interrogation of Prognostic Gene Expression Patterns: Exploring the Biology of Diffuse Large B Cell Lymphoma
por: Rimsza, Lisa M., et al.
Publicado: (2011)

Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma
por: Wang, Yucai, et al.
Publicado: (2019)

Clinical Treatment Guidelines for Tafasitamab plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
por: Nedved, Adrienne, et al.
Publicado: (2023)

RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma
por: Zinzani, Pier Luigi, et al.
Publicado: (2021)

P1287: DISTINGUISHING BETWEEN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA USING THE LYMPH3CX GENE EXPRESSION PROFILING ASSAY
por: Robetorye, R. S., et al.
Publicado: (2022)

PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts
por: Desai, Sanjal H., et al.
Publicado: (2022)

Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression
por: Tracy, Sean I., et al.
Publicado: (2018)

P1152: DEPTH OF METABOLIC RESPONSE AT INTERIM PET AND SURVIVAL OUTCOMES AMONG PATIENTS WITH PRIMARY REFRACTORY OR EARLY RELAPSING DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
por: Bock, Allison, et al.
Publicado: (2023)

Utilization of real‐world data in assessing treatment effectiveness for diffuse large B‐cell lymphoma
por: Nowakowski, Grzegorz, et al.
Publicado: (2022)

Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study
por: Tun, Aung M., et al.
Publicado: (2022)

Diffuse large B-cell lymphoma: the stuff of cell-of-origin and microenvironment
por: Pileri, Stefano A., et al.
Publicado: (2019)

Management of central nervous system relapse in a young patient affected by primary mediastinal large B‐cell lymphoma: A case report
por: Marangon, Miriam, et al.
Publicado: (2020)

ABCL-298 Diffuse Large B-Cell Lymphoma During the Covid-19 Pandemic in Two Tertiary Centers: The Israeli/Italian Study
por: Giladi, Odil, et al.
Publicado: (2022)

Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression
por: Bennani, N Nora, et al.
Publicado: (2022)

Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma
por: Rossi, Alessandra, et al.
Publicado: (2021)

Poster: ABCL-298 Diffuse Large B-Cell Lymphoma During the Covid-19 Pandemic in Two Tertiary Centers: The Israeli/Italian Study
por: Giladi, Odil, et al.
Publicado: (2022)

Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma
por: Derenzini, Enrico, et al.
Publicado: (2015)

PI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients
por: Tarantelli, Chiara, et al.
Publicado: (2021)

Novel Therapies for Aggressive B-Cell Lymphoma
por: Foon, Kenneth A., et al.
Publicado: (2012)

Diffuse Large B-Cell Lymphoma in Kenya: MYC, BCL2, and the Cell of Origin
por: Wawire, Jonathan, et al.
Publicado: (2019)

Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphoma
por: Novak, A J, et al.
Publicado: (2015)

The treatment of primary mediastinal large B-cell lymphoma: a two decades monocentric experience with 98 patients
por: Broccoli, Alessandro, et al.
Publicado: (2017)

Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine era
por: King, Rebecca L., et al.
Publicado: (2018)

Diffuse Large B-Cell Lymphoma in the Era of Precision Oncology: How Imaging Is Helpful
por: Shah, Hina J., et al.
Publicado: (2017)

Towards genomic-based prognostication and precision therapy for diffuse large B-cell lymphoma
por: Minderman, Marthe, et al.
Publicado: (2020)

PB2380: DEVELOPING GENOMIC TESTS THAT GUIDE LARGE B-CELL LYMPHOMA DIAGNOSIS AND TREATMENT: LYMPH2CX AND LYMPH3CX ASSAYS
por: Robetorye, Ryan S., et al.
Publicado: (2023)

Clinical laboratory validation of the MCL35 assay for molecular risk stratification of mantle cell lymphoma
por: Ramsower, Colleen A., et al.
Publicado: (2020)

A Novel Missense (M206K) STAT3 Mutation in Diffuse Large B Cell Lymphoma Deregulates STAT3 Signaling
por: Hu, Guangzhen, et al.
Publicado: (2013)

Controversies in the Treatment of Peripheral T-cell Lymphoma
por: Bachy, Emmanuel, et al.
Publicado: (2020)

Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study
por: Desai, Sanjal H., et al.
Publicado: (2021)

A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors
por: Tula-Sanchez, Ana A, et al.
Publicado: (2013)

Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based Therapy
por: Argnani, Lisa, et al.
Publicado: (2022)

High rate of event-free survival at 24 months with everolimus/RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance)
por: Witzig, T E, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_repkd5ahq3umk7mckr7jgk2ihg